Hira Siktel, MD
Internal Medicine · Chubbuck, IDNPI 1477790962
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $250, 2.7 times the $93 reported in 2019.
Across 42 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$192
- Novartis$124
- Otsuka America Pharmaceutical, Inc.$100
- Amgen$94
- AstraZeneca$71
- Novo Nordisk$55
- plus $189 from 8 others
Across 35 payments — averaging $128,492 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.1M
- Eli Lilly$154K
- Vertex$87K
- Travere Therapeutics, Inc.$62K
- Hoffmann-la Roche Limited$48K
- AbbVie$20K
What the payments were for
- Food & beverage$74590%
- Education$7910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 14 | $192 |
| Novartis | 6 | $124 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Amgen | 4 | $94 |
| AstraZeneca | 1 | $71 |
| Novo Nordisk | 2 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $30 |
| Fresenius USA Marketing, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Bayer | 1 | $17 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
| GSK | 1 | $14 |
How this compares
$824 in reported general payments places this provider in the 85th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 52 | $224,653 |
| FarxigaDapagliflozin Propanediol | 77 | $59,921 |
| AuryxiaFerric Citrate | 18 | $32,524 |
| RenvelaSevelamer Carbonate | 11 | $32,283 |
| Sevelamer Carbonate | 73 | $25,636 |
| DapagliflozinDapagliflozin Propanediol | 17 | $8,252 |
| Midodrine Hcl | 15 | $4,927 |
| Cinacalcet Hcl | 15 | $4,021 |
| Potassium Chloride | 64 | $2,824 |
| Calcitriol | 193 | $1,704 |
| Calcium Acetate | 11 | $1,418 |
| Losartan Potassium | 214 | $1,246 |
| Furosemide | 132 | $871 |
| Torsemide | 11 | $805 |
| Nifedipine ErNifedipine | 32 | $768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $26 | $224,65352 claims |
| AstraZenecaFarxiga | $71 | $59,92177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Chubbuck
- Tarek BarbarChubbuck$1K
- Sherwin D'souzaPocatello$543K
- Diana DumitrascuEagle$143K
- Huiling QiBoise$62K
- Aditya SinghPocatello$37K
- Carolyn BridgesBoise$27K
- Susan WachterIdaho Falls$22K
- Ahmed MahmoodIdaho Falls$21K
- Eric BensonPost Falls$19K
- Douglas AndersenPocatello$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.